AO-176 is a humanized IgG2 anti-CD47 mAb with attractive biologic characteristics, including preferential binding to tumor cells, minimal binding to RBCs, and a non-antibody dependent cellular cytotoxicity (ADCC) based killing mechanism [64], therefore, it has the potential to overcome toxicities seen in previous CD47-targeting agents. This evidence concerns the gene CD47 and neoplasm.